NRIX
Nurix Therapeutics, Inc.
$16.52
+1.47%
2026-05-08
About Nurix Therapeutics, Inc.
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.
Key Fundamentals
Forward P/E
-5.69
EPS (TTM)
$-3.17
ROE
-61.4%
Revenue Growth (YoY)
-66.1%
Profit Margin
0.0%
Debt/Equity
12.20
Price/Book
3.51
Beta
1.88
Market Cap
$1.69B
Avg Volume (10D)
820K
Recent Breakout Signals
No recent breakout signals detected for NRIX.
Recent Price Range (60 Days)
60D High
$17.68
60D Low
$14.01
Avg Volume
1.0M
Latest Close
$16.52
Get breakout alerts for NRIX
Sign up for Breakout Scanner to receive daily notifications when NRIX triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Nurix Therapeutics, Inc. (NRIX) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors NRIX daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. NRIX operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.